AU2012353330B2 - Chimeric double-stranded nucleic acid - Google Patents

Chimeric double-stranded nucleic acid Download PDF

Info

Publication number
AU2012353330B2
AU2012353330B2 AU2012353330A AU2012353330A AU2012353330B2 AU 2012353330 B2 AU2012353330 B2 AU 2012353330B2 AU 2012353330 A AU2012353330 A AU 2012353330A AU 2012353330 A AU2012353330 A AU 2012353330A AU 2012353330 B2 AU2012353330 B2 AU 2012353330B2
Authority
AU
Australia
Prior art keywords
modified
nucleic acid
base
rna
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012353330A
Other languages
English (en)
Other versions
AU2012353330A1 (en
Inventor
Hidehiro Mizusawa
Kazutaka Nishina
Satoshi Obika
Takanori Yokota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Medical and Dental University NUC
Original Assignee
Tokyo Medical and Dental University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Medical and Dental University NUC filed Critical Tokyo Medical and Dental University NUC
Publication of AU2012353330A1 publication Critical patent/AU2012353330A1/en
Application granted granted Critical
Publication of AU2012353330B2 publication Critical patent/AU2012353330B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
AU2012353330A 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid Active AU2012353330B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
JP2011-275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Publications (2)

Publication Number Publication Date
AU2012353330A1 AU2012353330A1 (en) 2014-07-31
AU2012353330B2 true AU2012353330B2 (en) 2018-04-19

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012353330A Active AU2012353330B2 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Country Status (9)

Country Link
US (5) US9816089B2 (zh)
EP (1) EP2791335B1 (zh)
JP (7) JP6112569B2 (zh)
CN (2) CN112386605A (zh)
AU (1) AU2012353330B2 (zh)
CA (2) CA3106312A1 (zh)
ES (1) ES2707232T3 (zh)
IN (1) IN2014CN04590A (zh)
WO (1) WO2013089283A1 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
CA3106312A1 (en) * 2011-12-16 2013-06-20 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
WO2014132671A1 (en) * 2013-03-01 2014-09-04 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
WO2014148620A1 (ja) * 2013-03-21 2014-09-25 国立大学法人東京医科歯科大学 二重鎖核酸結合剤、当該結合剤－二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法
US10190117B2 (en) * 2013-06-16 2019-01-29 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
US11116843B2 (en) 2015-09-25 2021-09-14 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3366773A4 (en) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX
EP3366774A4 (en) * 2015-10-23 2019-03-27 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX WITH AT LEAST ONE WOOD STRUCTURE
JP6950958B2 (ja) * 2015-12-01 2021-10-13 国立大学法人 東京医科歯科大学 核酸を含む経腸投与用組成物
CN116064544A (zh) * 2016-01-26 2023-05-05 日产化学株式会社 单链寡核苷酸
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
WO2018056442A1 (ja) * 2016-09-23 2018-03-29 国立大学法人東京医科歯科大学 血液脳関門通過型ヘテロ２本鎖核酸
EP3521430A4 (en) 2016-09-29 2020-05-20 National University Corporation Tokyo Medical and Dental University DOUBLE-STRANDED NUCLEIC ACID COMPLEX WITH OVERHEAD
CA3052801A1 (en) * 2017-02-06 2018-08-09 Nissan Chemical Corporation Single-stranded oligonucleotide
US11638717B2 (en) 2017-03-29 2023-05-02 Shionogi & Co., Ltd. Complex of nucleic acid medicine and multibranched lipid
WO2018180005A1 (ja) * 2017-03-31 2018-10-04 国立研究開発法人日本医療研究開発機構 コンドロイチン硫酸生合成を阻害するアンチセンス核酸
EP3647423A4 (en) * 2017-06-30 2021-03-24 National University Corporation Tokyo Medical and Dental University DOUBLE STRANDED HETERO-ANTI-MIRNA
US11555188B2 (en) 2017-07-26 2023-01-17 Nissan Chemical Corporation Single-stranded oligonucleotide
US11674141B2 (en) 2018-02-28 2023-06-13 National University Corporation Tokyo Medical And Dental University Ischemic-lesion-site-specific gene therapy
JP7333079B2 (ja) 2018-03-19 2023-08-24 国立大学法人 東京医科歯科大学 毒性が軽減した核酸
WO2019182294A1 (ko) * 2018-03-19 2019-09-26 주식회사 케이티 비디오 신호 처리 방법 및 장치
AU2019237599A1 (en) 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
JP7262816B2 (ja) * 2018-03-22 2023-04-24 国立大学法人 東京医科歯科大学 ヘテロ核酸のｂｂｂ通過脂質リガンド
CN113614232A (zh) * 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
JPWO2020209285A1 (zh) * 2019-04-08 2020-10-15
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
JPWO2021070959A1 (zh) * 2019-10-11 2021-04-15
EP4090744A4 (en) * 2020-01-17 2024-04-10 Anastasia Khvorova UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS
EP4098747A1 (en) 2020-01-31 2022-12-07 Sanwa Kagaku Kenkyusho Co., Ltd. Antisense oligonucleotide of atn1
EP4116419A1 (en) 2020-03-04 2023-01-11 Nissan Chemical Corporation Antisense oligonucleotide of calm2
WO2021187392A1 (ja) * 2020-03-16 2021-09-23 国立大学法人東京医科歯科大学 モルホリノ核酸を含むヘテロ核酸
CN115968374A (zh) 2020-06-15 2023-04-14 Liid制药股份有限公司 交联型核苷及核苷酸
CA3202708A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
US20240141414A1 (en) * 2021-02-26 2024-05-02 Northwestern University Cell-free biosensors with dna strand displacement circuits
WO2022250050A1 (ja) * 2021-05-25 2022-12-01 国立大学法人東京医科歯科大学 ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸
EP4353266A1 (en) 2021-05-31 2024-04-17 Rena Therapeutics Inc. Ligand-bound nucleic acid complex
JPWO2023022229A1 (zh) 2021-08-19 2023-02-23
JPWO2023026994A1 (zh) 2021-08-21 2023-03-02
WO2023042876A1 (ja) * 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 ２'－修飾ヌクレオシドを含むヘテロ核酸
WO2023105898A1 (ja) * 2021-12-07 2023-06-15 リードファーマ株式会社 アンチセンスオリゴヌクレオチド複合体
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20030104401A1 (en) 2001-11-12 2003-06-05 Epiclone, Inc. Gene silencing using sense DNA and antisense RNA hybrid constructs
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
US20040137471A1 (en) * 2002-09-18 2004-07-15 Timothy Vickers Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
CA2505801A1 (en) * 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
US7425544B2 (en) * 2003-09-18 2008-09-16 Eli Lilly And Company Modulation of eIF4E expression
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
BRPI0519690A2 (pt) 2004-12-30 2009-03-03 Todd M Hauser composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
WO2007134014A2 (en) 2006-05-05 2007-11-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gcgr
EP2057187B1 (en) 2006-08-10 2016-12-28 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
US20100216864A1 (en) 2006-10-09 2010-08-26 Ellen Marie Straarup RNA Antagonist Compounds for the Modulation of PCSK9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
WO2008111908A1 (en) * 2007-03-15 2008-09-18 Jyoti Chattopadhyaya Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer
EP2133425A1 (en) 2008-06-13 2009-12-16 Karin Mölling Method and compound for antiviral (HIV) therapy
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
WO2011046983A2 (en) * 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
CA3106312A1 (en) 2011-12-16 2013-06-20 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEKERLE V ET AL, "Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, (2005), vol. 8, no. 3, pages 516 - 527 *

Also Published As

Publication number Publication date
US9816089B2 (en) 2017-11-14
JP2022171811A (ja) 2022-11-11
JP2017140031A (ja) 2017-08-17
US20190270996A1 (en) 2019-09-05
CN112386605A (zh) 2021-02-23
JP6960123B2 (ja) 2021-11-05
US10337006B2 (en) 2019-07-02
US20210340540A1 (en) 2021-11-04
CA3106312A1 (en) 2013-06-20
JP7174384B2 (ja) 2022-11-17
CN104126010A (zh) 2014-10-29
JP2022000426A (ja) 2022-01-04
JP2018203779A (ja) 2018-12-27
IN2014CN04590A (zh) 2015-09-18
JP2020039364A (ja) 2020-03-19
US20140302603A1 (en) 2014-10-09
JP7423015B2 (ja) 2024-01-29
WO2013089283A1 (en) 2013-06-20
JP6638923B2 (ja) 2020-02-05
EP2791335B1 (en) 2018-11-14
JP6416301B2 (ja) 2018-10-31
CA2859581C (en) 2022-03-22
AU2012353330A1 (en) 2014-07-31
ES2707232T3 (es) 2019-04-03
JP6112569B2 (ja) 2017-04-12
CA2859581A1 (en) 2013-06-20
US11034955B2 (en) 2021-06-15
CN104126010B (zh) 2021-04-06
JP2015502134A (ja) 2015-01-22
EP2791335A1 (en) 2014-10-22
JP2021011501A (ja) 2021-02-04
US20180320181A1 (en) 2018-11-08
US20180073024A1 (en) 2018-03-15
US10329567B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
AU2012353330B2 (en) Chimeric double-stranded nucleic acid
US10526602B2 (en) Segmented micro RNA mimetics
JP2021527437A (ja) Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド
EP2898887B1 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2023011360A1 (zh) 一种增强核酸药物缓释能力的方法
EP3256586B1 (en) Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides
US20240158790A1 (en) Chimeric double-stranded nucleic acid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)